Life Technologies Chairman And CEO Gregory T. Lucier Named Penn State Outstanding Engineering Alumnus

    Life Technologies Chairman And CEO Gregory T. Lucier Named Penn State
                       Outstanding Engineering Alumnus

PR Newswire

UNIVERSITY PARK, Pa., April 5, 2013

UNIVERSITY PARK, Pa., April 5, 2013 /PRNewswire/ --Gregory T. Lucier,
Chairman and CEO of Life Technologies in Carlsbad, Calif, has been named an
Outstanding Engineering Alumnus by the Penn State College of Engineering in
recognition of his exceptional professional achievements.

Established in 1966, the award is the highest honor the College bestows on its
alumni. Lucier will be honored during a ceremony at the Nittany Lion Inn in
State College on April 9.

A 1986 graduate of Penn State with a bachelor's degree in industrial
engineering, Lucier fosters a culture of excellence at Life Technologies, a
global biotechnology company with a presence in more than 180 countries and
had sales of $3.8 billion in 2012. Ranked 9th among the world's 50 most
innovative companies, Life Technologies is a market leader in products and
services that accelerate advancements in basic research and drug development,
molecular diagnostics, 21st century forensics, regenerative science and
agricultural research. Today, he applies his more than 25 years of strategic
management experience in his endeavor to shape an era of personalized medicine
in which researchers can efficiently read, write and edit DNA for humanity's

After completing his M.B.A. at Harvard Business School, Lucier served in a
variety of leadership roles at General Electric (GE) Corporation, including
president and CEO of GE Medical Systems Information Technologies. After
joining Invitrogen Corporation in 2003, a leading supplier of life sciences
research tools, he led the 2008 merger between the company and Applied
Biosystems, a deal valued at more than $6.5 billion that formed Life
Technologies Corporation. Today, Lucier is driven to change the face of
healthcare and with a vision to see genomic-based medicine implemented to
guide targeted treatments of human disease in the near future. 

Lucier also serves on the Board of Directors at Synthetic Genomics, Inc.,
CareFusion Corporation, Rady Children's Hospital and the California Healthcare

Stefanie Tomlinson
Phone: 814-865-9031

SOURCE The Pennsylvania State University
Press spacebar to pause and continue. Press esc to stop.